The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis
The introduction of targeted therapy and immunotherapy has produced significant survival improvement in adenocarcinoma, with the most pronounced benefits with immunotherapy. Treatment efficacy varies across subgroups highlighting the need for further investigation to optimize personalized therapy.
Authors
- Taoying Li (ORCID: https://orcid.org/0000-0002-5081-8287)
- Fuhong Qin
- Zhanwu Li
- Mengmeng Teng
- Jianhua Zhou
- Jianwei Ji
Institutions
- Second Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1080/14737140.2026.2628946
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00